Find News

Filter articles

Applied Filters

Showing 61 to 70 of 1026 results

Allergan closes the book on Fetzima generics suit

US16-09-2021Alex Baldwin

Allergan has struck a deal with two generic manufacturers to resolve a long-running patent infringement suit over its antidepressant drug Fetzima.

FDA urges USPTO to tackle rising drug costs

US14-09-2021Muireann Bolger

The US Food and Drug Administration has urged the US Patent and Trademark Office (USPTO) to curb drug costs in the wake of President Joe Biden’s plan to promote competition in the pharmaceutical sector.

Pfizer to settle Xeljanz suit with Teva

US09-09-2021Alex Baldwin

Pfizer has asked a Delaware court to drop an infringement lawsuit against Teva Pharmaceuticals over a proposed generic of its rheumatoid arthritis drug Xeljanz.

Teva drops lawsuit with Amicus over Creates Act dispute

US07-09-2021Muireann Bolger

Teva Pharmaceuticals has abandoned its lawsuit against Amicus Therapeutics, which it had accused of contravening a US federal law designed to help generic makers bring cost-effective biosimilars to market.

Endo International can’t stop Vasostrict generic

US02-09-2021Alex Baldwin

The US District Court for the District of Delaware has ruled that one of Endo International’s pharma units cannot stop a generic of its blood pressure drug Vasostrict from being made.

Second Circuit says Takeda can’t dodge two antitrust suits

US26-08-2021Alex Baldwin

The US Court of Appeals for the Second Circuit has denied an appeal from Takeda Pharmaceuticals to shut down two antitrust suits related to its diabetes drug Actos.

Fed Circ upholds three Teva patents, axes others

US19-08-2021Alex Baldwin

The US Court of Appeals for the Federal Circuit has affirmed US Patent Trial and Appeal Board’s decisions upholding three patents related to Teva Pharmaceutical’s migraine drug Ajovy, but has invalidated six others.

Fed Circ upholds Teva cancer drug patents

US17-08-2021Alex Baldwin

The US Court of Appeals for the Federal Circuit has affirmed a Delaware court ruling upholding the validity of cancer drug patents owned by Teva Pharmaceuticals.

Fed Circuit split over $235m skinny label verdict

US10-08-2021Rory O'Neill

The US Court of Appeals for the Federal Circuit has reinstated a $235 million verdict against Teva in a split decision which could have major implications for skinny label generics.

Shionogi and Duchesnay add new patents to Osphena dispute

US05-08-2021Alex Baldwin

Pharmaceutical companies Shionogi and Duchesnay have filed a second lawsuit against Hetero labs, claiming that the company infringed two additional patents related to Osphena—a treatment for vaginal pain during sex.

Showing 61 to 70 of 1026 results